GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (OTCPK:MRMD) » Definitions » Capex-to-Operating-Cash-Flow

MariMed (MariMed) Capex-to-Operating-Cash-Flow : 1.13 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is MariMed Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

MariMed's Capital Expenditure for the three months ended in Mar. 2024 was $-3.63 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $3.21 Mil.

Hence, MariMed's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2024 was 1.13.


MariMed Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for MariMed's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Capex-to-Operating-Cash-Flow Chart

MariMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.46 0.52 1.74 2.62

MariMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4.50 0.76 1.66 1.13

Competitive Comparison of MariMed's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where MariMed's Capex-to-Operating-Cash-Flow falls into.



MariMed Capex-to-Operating-Cash-Flow Calculation

MariMed's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-20.756) / 7.91
=2.62

MariMed's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-3.633) / 3.21
=1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MariMed  (OTCPK:MRMD) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


MariMed Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of MariMed's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


MariMed (MariMed) Business Description

Traded in Other Exchanges
Address
10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.
Executives
Jon R Levine 10 percent owner C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Timothy Shaw officer: Chief Operating Officer C/O MARIMED INC, 10 OCEANA WAY, NORWOOD MA 02062
Kathleen Tucker director C/O 10 OCEANA WAY, 2ND FLOOR, NORWOOD MA 02062
Susan M. Villare officer: Chief Financial Officer C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Selhub Eva M.d. director C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
David R Allen director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Thomas Kidrin director 11 ROYAL ROAD, BROOKLINE MA 02445
Edward J Gildea director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Jay Coleman director 310 EAST 46TH ST. APT 9 F, NEW YORK NY 10017
Robert N Fireman director 145 ROSEMARY ST. SUITE H-2, NEEDHAM MA 02494
Worlds.com, Inc. director, 10 percent owner, officer: PRESIDENT, CEO, other: TREASURER, SECRETARY 11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan officer: CFO, VICE PRESIDENT 11 ROYAL RD, BROOKLINE MA 02445